Oxytocin Antagonist in Patients With Repeated Failure of Implantation

AZ Jan Palfijn Gent

Status and phase: Completed; Phase 4

Conditions: Implantation Failure

Treatments: Drug: placebo; Drug: Atosiban

Study type: Interventional

Funder types: Other

Identifiers

NCT01673399

2012-000278-49

Details and patient eligibility

About

In this study the investigators compare the usual way of embryo transfer (without medication) with an embryo transfer while administering oxytocine antagonist. This to improve implantation and increase the pregnancy rate.

Enrollment: 138 patients

Sex: Female

Ages: 18 to 38 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• IVF/ ICSI patients below 38 years
• 2e to 6e IVF-cycle

Exclusion criteria

• patients with endocrinological diseases or problems

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

138 participants in 2 patient groups, including a placebo group

Atosiban

Active Comparator group

Description:

Patients receive a bolus injection of 6.75mg atosiban and following an atosibaninfusion at 18mg/u during 3 hours.

Treatment:

Drug: Atosiban

placebo

Placebo Comparator group

Description:

Patients receive a placebo bolus injection (NaCl 0.9%)and an infusion of NaCl 0.9% during 3 hours

Treatment:

Drug: placebo